Activation of central angiotensin type 2 receptors by compound 21 improves arterial baroreflex sensitivity in rats with heart failure

American Journal of Hypertension

Volumn 27, Issue 10, 2014, Pages 1248-1256

  Gao, Juan ^a   Zucker, Irving H ^a   Gao, Lie ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Angiotensin type 2 receptor; Baroreflex; Blood pressure; Chronic heart failure; Compound 21; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; CARDIOVASCULAR AGENT; COMPOUND 21; HORMONE RECEPTOR STIMULATING AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NORADRENALIN; UNCLASSIFIED DRUG; N-BUTYLOXYCARBONYL-3-(4-IMIDAZOL-1-YLMETHYLPHENYL)-5-ISOBUTYLTHIOPHENE-2-SULFONAMIDE; SULFONAMIDE; THIOPHENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIAL BAROREFLEX SENSITIVITY; ARTICLE; BLOOD PRESSURE MEASUREMENT; BOLUS INJECTION; CARDIOVASCULAR FUNCTION; CONSCIOUSNESS; CONTROLLED STUDY; CORONARY ARTERY LIGATION; DOWN REGULATION; HEART FAILURE; HEART RATE; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; NORADRENALIN URINE LEVEL; OSMOTIC MINIPUMP; PARAVENTRICULAR THALAMIC NUCLEUS; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL SYMPATHETIC NERVE ACTIVITY; ROSTRAL VENTROLATERAL MEDULLA; SOLITARY TRACT NUCLEUS; SUBFORNICAL ORGAN; SYMPATHETIC NERVE; TELEMETRY; UPREGULATION; URINALYSIS; WESTERN BLOTTING; ADRENERGIC SYSTEM; AGONISTS; ANIMAL; BLOOD PRESSURE; BRAIN; DRUG EFFECTS; INNERVATION; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; KIDNEY; METABOLISM; SPRAGUE DAWLEY RAT;

ANIMALS; BAROREFLEX; BLOOD PRESSURE; BRAIN; HEART FAILURE; HEART RATE; INFUSIONS, INTRAVENTRICULAR; KIDNEY; MALE; NITRIC OXIDE SYNTHASE TYPE I; NOREPINEPHRINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SULFONAMIDES; SYMPATHETIC NERVOUS SYSTEM; THIOPHENES;

EID: 84986902830     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/hpu044     Document Type: Article

References (39)

1. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311:819-823.
2. Goldstein DS. Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology. Am J Cardiol 1981; 48:1147-1154.
3. Malliani A, Pagani M. The role of the sympathetic nervous system in congestive heart failure. Eur Heart J 1983; 4:49-54.
4. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, Mammi C, Piepoli M, Fini M, Rosano GM. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol 2009; 54:919-927.
5. Roveda F, Middlekauff HR, Rondon MU, Reis SF, Souza M, Nastari L, Barretto AC, Krieger EM, Negrao CE. The effects of exercise training on sympathetic neural activation in advanced heart failure: a randomized controlled trial. J Am Coll Cardiol 2003; 42:854-860.
6. Zucker IH. Novel mechanisms of sympathetic regulation in chronic heart failure. Hypertension 2006; 48:1005-1011.
7. Wang WZ, Gao L, Pan YX, Zucker IH, Wang W. AT1 receptors in the nucleus tractus solitarii mediate the interaction between the baroreflex and the cardiac sympathetic afferent reflex in anesthetized rats. Am J Physiol Regul Integr Comp Physiol 2007; 292:R1137-R1145.
8. Elder DH, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, Rekhraj S, Lim TK, George J, Doney A, Pringle SD, Choy AM, Struthers AD, Lang CC. The impact of renin-angiotensin-aldosterone system blockade on heart failure outcomes and mortality in patients identified to have aortic regurgitation: a large population cohort study. J Am Coll Cardiol 2011; 58:2084-2091.
9. Porrello ER, D'Amore A, Curl CL, Allen AM, Harrap SB, Thomas WG, Delbridge LM. Angiotensin II type 2 receptor antagonizes angiotensin II type 1 receptor-mediated cardiomyocyte autophagy. Hypertension 2009; 53:1032-1040.
10. Gao L, Wang W, Wang W, Li H, Sumners C, Zucker IH. Effects of angiotensin type 2 receptor overexpression in the rostral ventrolateral medulla on blood pressure and urine excretion in normal rats. Hypertension 2008; 51:521-527.
11. Gao J, Zhang H, Le KD, Chao J, Gao L. Activation of central angiotensin type 2 receptors suppresses norepinephrine excretion and blood pressure in conscious rats. Am J Hypertens 2011; 24:724-730.
12. Gao L, Wang WZ, Wang W, Zucker IH. Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension 2008; 52:708-714.
13. Unger T, Dahlof B. Compound 21, the first orally active, selective agonist of the angiotensin type 2 receptor (AT2): implications for AT2 receptor research and therapeutic potential. J Renin Angiotensin Aldosterone Syst 2010; 11:75-77.
14. Wan Y, Wallinder C, Plouffe B, Beaudry H, Mahalingam AK, Wu X, Johansson B, Holm M, Botoros M, Karlen A, Pettersson A, Nyberg F, Fandriks L, Gallo-Payet N, Hallberg A, Alterman M. Design, synthesis, and biological evaluation of the first selective nonpeptide AT2 receptor agonist. J Med Chem 2004; 47:5995-6008.
15. Lauer D, Slavic S, Sommerfeld M, Thone-Reineke C, Sharkovska Y, Hallberg A, Dahlof B, Kintscher U, Unger T, Steckelings UM, Kaschina E. Angiotensin type 2 receptor stimulation ameliorates left ventricular fibrosis and dysfunction via regulation of tissue inhibitor of matrix metalloproteinase 1/matrix metalloproteinase 9 axis and transforming growth factor beta1 in the rat heart. Hypertension, 2014; 63:e60-e67.
16. Kaschina E, Grzesiak A, Li J, Foryst-Ludwig A, Timm M, Rompe F, Sommerfeld M, Kemnitz UR, Curato C, Namsolleck P, Tschope C, Hallberg A, Alterman M, Hucko T, Paetsch I, Dietrich T, Schnackenburg B, Graf K, Dahlof B, Kintscher U, Unger T, Steckelings UM. Angiotensin II type 2 receptor stimulation: a novel option of therapeutic interference with the renin-angiotensin system in myocardial infarction? Circulation 2008; 118:2523-2532.
17. Paulis L, Becker ST, Lucht K, Schwengel K, Slavic S, Kaschina E, Thone-Reineke C, Dahlof B, Baulmann J, Unger T, Steckelings UM. Direct angiotensin II type 2 receptor stimulation in Nomega-nitro-L-argininemethyl ester-induced hypertension: the effect on pulse wave velocity and aortic remodeling. Hypertension 2012; 59:485-492.
18. Rehman A, Leibowitz A, Yamamoto N, Rautureau Y, Paradis P, Schiffrin EL. Angiotensin type 2 receptor agonist compound 21 reduces vascular injury and myocardial fibrosis in stroke-prone spontaneously hypertensive rats. Hypertension 2012; 59:291-299.
19. Lemarie CA, Schiffrin EL. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010; 11:19-31.
20. Sharma NM, Zheng H, Mehta PP, Li YF, Patel KP. Decreased nNOS in the PVN leads to increased sympathoexcitation in chronic heart failure: role for CAPON and Ang II. Cardiovasc Res 2011; 92:348-357.
21. Sharma NM, Zheng H, Li YF, Patel KP. Nitric oxide inhibits the expression of AT1 receptors in neurons. Am J Physiol Cell Physiol 2012; 302:C1162-C1173.
22. Kent BB, Drane JW, Blumenstein B, Manning JW. A mathematical model to assess changes in the baroreceptor reflex. Cardiology 1972; 57:295-310.
23. Paxinos G, Watson C. The Rat Brain in Stereotaxic Coordinates. 6th ed. Elsevier Academic Press: Burlington, MA, 2008.
24. Millar-Craig MW, Bishop CN, Raftery EB. Circadian variation of blood-pressure. Lancet 1978; 1:795-797.
25. Zhang B, Sannajust F. Diurnal rhythms of blood pressure, heart rate, and locomotor activity in adult and old male Wistar rats. Physiol Behav 2000; 70:375-380.
26. de GM, Catt KJ, Inagami T, Wright JW, Unger T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 2000; 52:415-472.
27. Veerasingham SJ, Raizada MK. Brain renin-angiotensin system dysfunction in hypertension: recent advances and perspectives. Br J Pharmacol 2003; 139:191-202.
28. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Superoxide mediates sympathoexcitation in heart failure: roles of angiotensin II and NAD(P)H oxidase. Circ Res 2004; 95:937-944.
29. Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlof B, Unger T. Non-peptide AT2-receptor agonists. Curr Opin Pharmacol 2011; 11:187-192.
30. Bosnyak S, Welungoda IK, Hallberg A, Alterman M, Widdop RE, Jones ES. Stimulation of angiotensin AT2 receptors by the non-peptide agonist, compound 21, evokes vasodepressor effects in conscious spontaneously hypertensive rats. Br J Pharmacol 2010; 159:709-716.
31. Gelosa P, Pignieri A, Fandriks L, de GM, Hallberg A, Banfi C, Castiglioni L, Turolo L, Guerrini U, Tremoli E, Sironi L. Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. J Hypertens 2009; 27:2444-2451.
32. Matavelli LC, Huang J, Siragy HM. Angiotensin AT(2) receptor stimulation inhibits early renal inflammation in renovascular hypertension. Hypertension 2011; 57:308-313.
33. Zucker IH, Wang W, Pliquett RU, Liu JL, Patel KP. The regulation of sympathetic outflow in heart failure. The roles of angiotensin II, nitric oxide, and exercise training. Ann N Y Acad Sci 2001; 940:431-443.
34. Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther 2008; 326:278-285.
35. Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG, Zucker IH. Simvastatin therapy normalizes sympathetic neural control in experimental heart failure: roles of angiotensin II type 1 receptors and NAD(P)H oxidase. Circulation 2005; 112:1763-1770.
36. Chan SH, Hsu KS, Huang CC, Wang LL, Ou CC, Chan JY. NADPH oxidase-derived superoxide anion mediates angiotensin II-induced pressor effect via activation of p38 mitogen-activated protein kinase in the rostral ventrolateral medulla. Circ Res 2005; 97:772-780.
37. Zheng H, Sharma NM, Liu X, Patel KP. Exercise training normalizes enhanced sympathetic activation from the paraventricular nucleus in chronic heart failure: role of angiotensin II. Am J Physiol Regul Integr Comp Physiol 2012; 303:R387-R394.
38. Llewellyn TL, Sharma NM, Zheng H, Patel KP. Effects of exercise training on SFO-mediated sympathoexcitation during chronic heart failure. Am J Physiol Heart Circ Physiol 2014; 306:H121-H131.
39. Tan PS, Potas JR, Killinger S, Horiuchi J, Goodchild AK, Pilowsky PM, Dampney RA. Angiotensin II evokes hypotension and renal sympathoinhibition from a highly restricted region in the nucleus tractus solitarii. Brain Res 2005; 1036:70-76.